PRN Archives - Page 8 of 11

Developments

Analysts see EAU data broadening utility of Profound Medical’s TULSA-PRO

Analysts for Raymond James and Cowen say two posters to be presented at the European Association of Urology (EAU) virtual conference in mid-July enhance the clinical utility of Profound Medical’s (NASDAQ:PROF;...

June 11, 2020

Markets

Raymond James adds Profound Medical to “analyst current favorite”

Raymond James added Profound Medical (TSX:PRN; NASDAQ:PROF) as an “analyst current favorite,” maintaining a “strong buy” recommendation, after AstraZeneca and Merck received FDA approval for their PARP inhibitor drug...

May 22, 2020

Developments

Profound Medical launches TULSA patient website in U.S.

Profound Medical (NASDAQ:PROF; TSX:PRN) launched a newly designed TULSA Procedure website, for residents of the U.S. suffering from a prostate condition. “This new site aims to be credible and focused on providing clear...

April 3, 2020

Markets

Cowen starts Profound Medical at OP; PT $15 (U.S.)

Cowen launched coverage of Profound Medical (NASDAQ:PROF; TSX:PRN) with an “outperform” rating and $15 (U.S.) price target. The stock closed at $9.74 on March 31. “[Profound’s] TULSA-PRO is a proprietary platform that...

April 1, 2020

Developments

Profound Medical’s TULSA-PRO now available at Georgia’s renowned Busch Center

Georgia’s renowned Busch Center is now offering Profound Medical’s (NASDAQ:PROF; TSX:PRN) TULSA-PRO procedure to treat unhealthy prostate tissue. The technology, which was cleared by the FDA in August 2019, provides...

March 26, 2020

Markets

Mackie Research ups Profound Medical to speculative buy

Mackie Research upgraded Profound Medical (TSX:PRN; NASDAQ:PROF) to “speculative buy” from “hold,” but reduced its price target to $16.20 from $26.10 due to the anticipated impact of the coronavirus. The stock closed at...

March 24, 2020

Markets

Raymond James sees Profound Medical insulated from COVID-19 fallout

Raymond James reiterated that Profound Medical (TSX:PRN; NASDAQ:PROF) remains its “analyst current favorite” and “2020 Best Pick,” saying Profound is “particularly insulated from the current economic fallout of COVID-19...

March 12, 2020

Developments

Profound Medical retires bank debt ahead of schedule

Profound Medical (TSX:PRN; NASDAQ:PROF) retired its $12.5-million in principal amount loan with Canadian Imperial Bank of Commerce, maturing July 29, 2022. “We are pleased to have repaid the CIBC loan almost 30 months...

February 5, 2020

Markets

Canaccord ups Profound Medical PT to $20 from $14

Canaccord Genuity raised its price target for Profound Medical (NASDAQ:PROF; TSX:PRN) to $20 from $14 after the company announced preliminary Q4-2019 results. Shares of Profound were quoted at $14.72, up $1.73, or 13%...

January 10, 2020

Developments

Health Canada approves Profound Medical’s TULSA-PRO system

Health Canada approved the sale of Profound Medical’s (NASDAQ:PROF; TSX:PRN) TULSA-PRO system for the ablation of low-to intermediate-risk organ-confined prostate cancer. TULSA-PRO is a transurethral prostate tissue...

November 25, 2019

Tag - PRN

Analysts see EAU data broadening utility of Profound Medical’s TULSA-PRO

Raymond James adds Profound Medical to “analyst current favorite”

Profound Medical launches TULSA patient website in U.S.

Cowen starts Profound Medical at OP; PT $15 (U.S.)

Profound Medical’s TULSA-PRO now available at Georgia’s renowned Busch Center

Mackie Research ups Profound Medical to speculative buy

Raymond James sees Profound Medical insulated from COVID-19 fallout

Profound Medical retires bank debt ahead of schedule

Canaccord ups Profound Medical PT to $20 from $14

Health Canada approves Profound Medical’s TULSA-PRO system

Subscribe